НовостиBenzingaRBC Capital Maintains Outperform on BeOne Medicines, Raises Price Target to $465 RBC Capital Maintains Outperform on BeOne Medicines, Raises Price Target to $465 Benzinga 2026.11.06 17:57 (GMT+0) Открыть на Benzinga Другие новости